Payment overview · 2025
General Payments
$74,961.38
102 reported records · 5 companies
Healthcare provider profile · identity verified
Ronald Collazo Pagan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MANATI, PR · NPI 1194958041
Verified facts
What the public records show
CMS Open Payments records show Ronald Collazo Pagan, M.D. received $74,961.38 in general payments during 2025 across 102 reported records.
ViiV Healthcare Company accounted for 85.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Pifeltro, Symtuza.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Descovy by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMTUZA as an associated drug or biological on 44 records involving 34 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symtuza by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PIFELTRO as an associated drug or biological on 7921 records involving 2912 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Pifeltro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $64,062.20 | 85.5% | 74 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $9,588.07 | 12.8% | 22 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $1,256.15 | 1.7% | 4 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $29.96 | 0.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.00 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $51,825.00 | 18 |
| Travel and Lodging | $12,116.18 | 34 |
| Consulting Fee | $7,600.00 | 1 |
| Food and Beverage | $3,420.20 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $62,535.65 | 61 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $9,130.66 | 16 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $131.15 | 3 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $31.15 | 2 | 2025 |
Source payment records
|
|||||
| SYMTUZA Normalized: symtuza |
Drug | Janssen Pharmaceuticals, Inc | $29.96 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $25.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| PIFELTRO pifeltro |
2025 | Pifeltro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYMTUZA symtuza |
2025 | Symtuza | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | SYMTUZA open payments reported associated product |
CMS Open Payments — General Payments 44 supporting records · 34 recipient NPIs · example record 1174329506 |
Symtuza · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | PIFELTRO open payments reported associated product |
CMS Open Payments — General Payments 7921 supporting records · 2912 recipient NPIs · example record 1237992198 |
Pifeltro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 254 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 184 | 54 |
| Synthroid | Levothyroxine Sodium | 172 | 49 |
| Famotidine | Famotidine | 164 | 50 |
| Atorvastatin Calcium | Atorvastatin Calcium | 162 | 50 |
| Losartan Potassium | Losartan Potassium | 156 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 136 | 35 |
| Metformin Hcl | Metformin Hcl | 132 | 32 |
| Simvastatin | Simvastatin | 122 | 36 |
| Amlodipine Besylate | Amlodipine Besylate | 114 | 38 |
| Omeprazole | Omeprazole | 102 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 98 | 30 |
| Lisinopril | Lisinopril | 87 | 31 |
| Clonazepam | Clonazepam | 83 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 77 | 25 |
| Montelukast Sodium | Montelukast Sodium | 75 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 67 | 20 |
| Temazepam | Temazepam | 64 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 53 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 19 |
| Irbesartan | Irbesartan | 49 | 19 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 48 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 21 |
| Donepezil Hcl | Donepezil Hcl | 45 | suppressed |
| Alprazolam | Alprazolam | 44 | suppressed |
| Atenolol | Atenolol | 43 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 42 | 17 |
| Glimepiride | Glimepiride | 42 | 14 |
| Alendronate Sodium | Alendronate Sodium | 40 | 11 |
| Eliquis | Apixaban | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 38 | 19 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 12 |
| Enalapril Maleate | Enalapril Maleate | 36 | 11 |
| Ezetimibe | Ezetimibe | 36 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Azithromycin | Azithromycin | 35 | 32 |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Carvedilol | Carvedilol | 35 | 14 |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 34 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 34 | 17 |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Methylprednisolone | Methylprednisolone | 31 | 26 |
| Allopurinol | Allopurinol | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | 16 |
| Prednisone | Prednisone | 30 | 12 |
| Furosemide | Furosemide | 29 | 12 |
| Glipizide | Glipizide | 27 | suppressed |
| Meloxicam | Meloxicam | 27 | 13 |
| Sertraline Hcl | Sertraline Hcl | 27 | 11 |
| Ketoconazole | Ketoconazole | 26 | suppressed |
| Sucralfate | Sucralfate | 25 | 11 |
| Valsartan | Valsartan | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 16 |
| Jardiance | Empagliflozin | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 23 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 22 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 22 | suppressed |
| Tivicay | Dolutegravir Sodium | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Dexamethasone | Dexamethasone | 17 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 16 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 13 |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Baclofen | Baclofen | 13 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Pifeltro | Doravirine | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $74,961.38 · 102 records | ViiV Healthcare Company | APRETUDE, CABENUVA, CAPVAXIVE, Cologuard Collection Kit, GARDASIL 9, PIFELTRO, SYMTUZA, Yeztugo | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Pifeltro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error